Status:
COMPLETED
Participant Reported Outcomes and Treatment Experiences in Kidney Cancer
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Kidney Cancer
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this observational study is to collect contemporary real-world treatment patterns, clinical outcomes, humanistic burden (including patient-reported disease-specific Health-related Quali...
Eligibility Criteria
Inclusion
- For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
- Cohort 1
- Primary diagnosis of aRCC (advanced Renal Cell Carcinoma) or metastatic RCC
- Medical history must be available from date of aRCC diagnosis
- Initiated 1LOT between April 2018 - March 2020
- Cohort 2:
- Primary diagnosis of aRCC (not amenable to curative surgery or radiation therapy/ AJCC Stage III unresectable) or metastatic RCC (AJCC Stage IV).
- Medical history must be available from date of aRCC diagnosis.
- Initiate 1LOT.
Exclusion
- Currently enrolled in a clinical trial for treatment of aRCC
- Any prior malignancy active within the previous 3 year, except for locally curable cancers that have been cured
- Any prior systemic therapy for aRCC, with the exception of neoadjuvant or adjuvant therapy (Cohort 2 only)
- Other protocol-defined inclusion/exclusion criteria apply
Key Trial Info
Start Date :
July 6 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 9 2020
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT04472663
Start Date
July 6 2020
End Date
December 9 2020
Last Update
April 26 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
Morristown, New Jersey, United States, 07960